









Markets
/
Stocks
/
nasdaq-ino
/

Inovio Pharmaceuticals Inc

INO

1.660USD

+0.100+6.41%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

88.93MMarket Cap

LossP/E TTM



Inovio Pharmaceuticals Inc

1.660

+0.100+6.41%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Inovio Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Inovio Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 115 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.56.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Inovio Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

115 / 392

Overall Ranking

249 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Inovio Pharmaceuticals Inc Highlights

StrengthsRisks

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.

Growing

The company is in a growing phase, with the latest annual income totaling USD 217.76K.

Fairly Valued

The company’s latest PE is -0.61, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 25.25M shares, increasing 31.19% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 3.03K shares of this stock.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

8.560

Target Price

+448.72%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Inovio Pharmaceuticals Inc is 7.29, ranking 127 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.35

Change

-0.06



Financials

7.42

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.59

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.85

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.60

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Inovio Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Inovio Pharmaceuticals Inc is 8.24, ranking 56 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.61, which is -95.92% below the recent high of -0.02 and -166.62% above the recent low of -1.63.

Score

Industry at a Glance

Previous score

8.24

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 115/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Inovio Pharmaceuticals Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 13.00 and a low of 1.80.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

8.560

Target Price

+448.72%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Inovio Pharmaceuticals Inc

INO

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Inovio Pharmaceuticals Inc is 5.79, ranking 294 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.80 and the support level at 1.49, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.40

Change

0.39

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.060

Neutral

RSI(14)

48.898

Neutral

STOCH(KDJ)(9,3,3)

53.487

Neutral

ATR(14)

0.099

High Vlolatility

CCI(14)

78.682

Neutral

Williams %R

38.710

Buy

TRIX(12,20)

-0.545

Sell

StochRSI(14)

78.830

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.656

Buy

MA10

1.609

Buy

MA20

1.581

Buy

MA50

1.844

Sell

MA100

2.069

Sell

MA200

1.987

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Inovio Pharmaceuticals Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 36.76%, representing a quarter-over-quarter increase of 75.20%. The largest institutional shareholder is The Vanguard, holding a total of 3.32M shares, representing 4.83% of shares outstanding, with 12.77% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Alyeska Investment Group, L.P.

4.00M

Adage Capital Management, L.P.

3.43M

The Vanguard Group, Inc.

Star Investors

2.71M

+35.03%

Janus Henderson Investors

3.27M

Boxer Capital Management, LLC

2.30M

Millennium Management LLC

1.97M

+468.67%

Renaissance Technologies LLC

Star Investors

816.34K

+148.79%

D. E. Shaw & Co., L.P.

806.74K

Morgan Stanley & Co. LLC

752.80K

+202.39%

BofA Global Research (US)

636.06K

-49.94%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Inovio Pharmaceuticals Inc is 3.17, ranking 168 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.74. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.